Pharmigene's revenue is increased this year due to those certified/licensed pharmacogenomic IVD products, with the boost of recently obtained KFDA approval and previous CFDA approval for HLA-B*1502/HLA-B*5801 kits.
HLA-B*5801 testing obtained South Korea MFDS approval of class III medical devices. Phargmigene is going to provide kits for major medical centers and clinical laboratories in Korea from November.